COVID-19 疫苗犹豫及其与原发孔源性视网膜脱离表现改变的关系
该单中心临床队列研究纳入 2020 年 12 月 14 日至 2021 年 12 月 12 日连续就诊的原发孔源性视网膜脱离患者,分为已接种、后续接种和始终未接种三组。结果显示,与已接种组相比,后续接种组和始终未接种组黄斑脱离和原发增殖性玻璃体视网膜病变比例更高,且始终未接种组失访比例更高、就医距离更远,已接种组初始和最终最佳矫正视力更好。
要点
- 后续接种组和始终未接种组黄斑脱离比例高于已接种组(54%、57.9% 对比 44.5%,P<.0001)。
- 始终未接种组失访比例 7.7%,高于已接种组 2.3% 和后续接种组 2.2%(P<.0001)。
- 已接种组初始和最终最佳矫正视力均优于后续接种组和始终未接种组(P<.05)。
核心结论
- COVID-19 疫苗犹豫与原发孔源性视网膜脱离更差的临床表现和结局相关。
研究设计与样本
- 单中心临床队列研究,纳入 2020 年 12 月 14 日至 2021 年 12 月 12 日连续就诊的原发孔源性视网膜脱离患者共 1047 例。
- 患者分为已接种组 391 例、后续接种组 252 例和始终未接种组 404 例。
主要发现
- 黄斑脱离比例:已接种组 44.5%,后续接种组 54%(P<.0001),始终未接种组 57.9%(P<.0001)。
- 原发增殖性玻璃体视网膜病变比例:已接种组 4.3%,后续接种组 13.6%(P<.0001),始终未接种组 17.1%(P<.0001)。
- 失访比例:始终未接种组 7.7%,已接种组 2.3%,后续接种组 2.2%(P<.0001)。
- 就医距离中位数:始终未接种组 35 英里,已接种组 22.3 英里(P<.0001),后续接种组 25.45 英里(P=.0038)。
- 最佳矫正视力中位数(logMAR):已接种组初始 0.30、最终 0.18,后续接种组初始 0.54、最终 0.30,始终未接种组初始 0.70、最终 0.40(P<.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Evaluate factors associated with coronavirus 2019 (COVID-19) vaccine hesitancy and clinical trends in primary rhegmatogenous retinal detachments (RRDs) during the first year of vaccine availability. DESIGN: Single-center, clinical cohort study. METHODS: Consecutive patients from December 14, 2020, to December 12, 2021, presenting vaccinated (Prior-), subsequently vaccinated (Later-), or remaining unvaccinated (Never-Vax). Primary outcome was proportion with macula-off (mac-off) RRD. Secondary outcomes included logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity (BCVA), primary proliferative vitreoretinopathy (PVR), proportion lost to follow-up, and distance traveled. RESULTS: 1047 patients were divided into 391 Prior-, 252 Later-, and 404 Never-Vax cohorts. Significantly greater proportions of Later- and Never-Vax cohorts presented with mac-off RRDs (Prior-Vax = 44.5%; Later-Vax = 54%, P < .0001; Never-Vax = 57.9%, P < .0001) and primary PVR (Prior-Vax = 4.3%; Later-Vax = 13.6%, P < .0001; Never-Vax = 17.1%, P < .0001) compared to Prior-Vax cohort. Significantly greater proportion of Never-Vax cohort (7.7%, P < .0001) were lost to follow-up compared to Prior- (2.3%) and Later-Vax (2.2%) cohorts. Never-Vax cohort (median = 35 miles) traveled farther compared to Prior- (median = 22.3 miles; P < .0001) and Later-Vax cohorts (25.45 miles; P = .0038). Prior-Vax cohort had significantly better (P < .05) initial (median = 0.30 logMAR) and final (0.18 logMAR) BCVA compared to Later- (Initial: 0.54 logMAR; Final: 0.30 logMAR) and Never-Vax (Initial: 0.70 logMAR; Final: 0.40 logMAR) cohorts. CONCLUSIONS: COVID-19 vaccine hesitancy is associated with worse clinical presentation and outcomes for primary RRD.
引用
- Mundae R, Wagley S, Ryan EH, et al. COVID-19 Vaccination Hesitancy and Its Association With Altered Presentation of Primary Rhegmatogenous Retinal Detachment. Am J Ophthalmol. 2022. PMID: 35609676. doi:10.1016/j.ajo.2022.05.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。